TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21604490

Group type: EXPERIMENTAL
Intervention: 15 mg lansoprazole IV infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole IV infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 60 mg lansoprazole IV infusion
Number of subjects: 12
Study: 19526756

Group type: EXPERIMENTAL
Intervention: Shengmai Injection (SMI)
Number of subjects: 40
Study: 16924025

Group type: EXPERIMENTAL
Intervention: GABRG2 mutation analysis
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Electrophysiologic studies
Number of subjects: 47
Study: 15037271

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.05‐0.1 mg/kg per hour)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nitroglycerin (0.25‐2.5 microg/kg per minute)
Number of subjects: 60
Study: 11282569

Group type: EXPERIMENTAL
Intervention: Maharishi Vedic Vibration Technology (MVVT)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 176
Study: 9390110

Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.83 mg/hr for 7 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Linsidomine (SIN-1)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8198935

Group type: EXPERIMENTAL
Intervention: Dopamine (DA) at 2.5 micrograms kg‐1 min‐1
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 17
Study: 3283777

Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline ('Trental') 3-times daily
Number of subjects: 76

Group type: COMPARATOR
Intervention: 75 mg cinnarizine 3-times daily
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline ('Trental')
Number of subjects: 76

Group type: COMPARATOR
Intervention: 75 mg cinnarizine
Number of subjects: 76
Study: 30247751

Group type: EXPERIMENTAL
Intervention: Placebo beverages
Number of subjects: 240
Study: 27164434

Group type: EXPERIMENTAL
Intervention: Abacavir/3TC (ABC/3TC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 39
Study: 25326140

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Breathing exercises (BG)
Number of subjects: 48
Study: 23565616

Group type: EXPERIMENTAL
Intervention: Antiviral treatment with telbivudine
Number of subjects: 84

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 84
Study: 20057999

Group type: EXPERIMENTAL
Intervention: Linear Periodization Group (LPG, n = 14)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Undulating Periodization Group (UPG, n = 13)
Number of subjects: 27
Study: 17241768

Group type: EXPERIMENTAL
Intervention: Functional voice therapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 184
Study: 17120738

Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin 400 mg once a day for 7 to 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefoperazone 2.0 g twice a day and azithromycin 0.5 g once a day for 7 to 14 days
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin 400 mg once a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cefoperazone 2.0 g twice a day and azithromycin 0.5 g once a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both moxifloxacin and cefoperazone plus azithromycin
Number of subjects: 40
Study: 12838104

Group type: EXPERIMENTAL
Intervention: Large-array surface electromyography in patients with acute low back pain (n = 13)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Large-array surface electromyography in patients with chronic low back pain (n = 25)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Large-array surface electromyography in healthy pain-free controls (n = 163)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Large-array surface electromyography in patients with acute low back pain (n = 3) whose pain resolved during the study
Number of subjects: 201
Study: 10952121

Group type: EXPERIMENTAL
Intervention: Platinum/paclitaxel combination chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cisplatin/cyclophosphamide combination chemotherapy
Number of subjects: 0
Study: 9085457

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ethanol (0.15 g/kg and 0.45 g/kg)
Number of subjects: 12
Study: 7524382

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with lidocaine (1 mg/kg) combined with moradol (0.005 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spinal anesthesia with lidocaine (1 mg/kg) combined with morphine (0.01 mg/kg)
Number of subjects: 0
Study: 3760659

Group type: EXPERIMENTAL
Intervention: Knee-to-chest position
Number of subjects: 146

Group type: COMPARATOR
Intervention: Dorsal position
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Rigid external sleeve added to catheter
Number of subjects: 146

Group type: COMPARATOR
Intervention: Standard replacement method
Number of subjects: 146
Study: 28243787

Group type: EXPERIMENTAL
Intervention: Animal protein breakfast (milk)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Plant protein breakfast (oat, pea, potato)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 50:50 mixture of animal and plant proteins
Number of subjects: 28

Group type: COMPARATOR
Intervention: Carbohydrate-rich meal
Number of subjects: 28
Study: 27471879

Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 184
Study: 24725238

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 12 weeks
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 12 weeks
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir for 24 weeks
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Ledipasvir-sofosbuvir plus ribavirin for 24 weeks
Number of subjects: 440
Study: 22510600

Group type: EXPERIMENTAL
Intervention: 7.2 Gy × 3 fractions
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: 6 Gy × 4 fractions
Number of subjects: 377
Study: 20166163

Group type: EXPERIMENTAL
Intervention: Radiant infrared (IR) light emitting diode (LED) (970 nm) pre-treatment for 15 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control side (no IR pre-treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Radiant IR pre-treatment
Number of subjects: 10
Study: 19065863

Group type: EXPERIMENTAL
Intervention: Monolingual participants judging dots moving left to right
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bilingual participants
Number of subjects: 0
Study: 15851429

Group type: EXPERIMENTAL
Intervention: Ventilation tubes
Number of subjects: 1234
Study: 12423433

Group type: EXPERIMENTAL
Intervention: Acitretin (25 mg daily or on alternate days)
Number of subjects: 23
Study: 10509496

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (n=48)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no nitric oxide, n=32)
Number of subjects: 80
Study: 8606612

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Small-incision cholecystectomy
Number of subjects: 200
Study: 1726521

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid with UVB therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Indifferent ointment (control) with UVB therapy
Number of subjects: 30
Study: 7034553

Group type: EXPERIMENTAL
Intervention: Tight clothing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loose fitted dresses
Number of subjects: 0
Study: 31239010

Group type: EXPERIMENTAL
Intervention: Transtheoretical model (TTM)‐based tailored behavioral intervention (TBI)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Non‐tailored intervention (NTI)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 533
Study: 30046129

Group type: EXPERIMENTAL
Intervention: Probiotic (Lactobacillus rhamnosus R0011 and Lactobacillus helveticus R0052)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanic Acid
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27769263

Group type: EXPERIMENTAL
Intervention: Multifaceted implementation strategy (MuIS)
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Passive implementation strategy (PaIS)
Number of subjects: 1101
Study: 25377958

Group type: EXPERIMENTAL
Intervention: Virtual diagnostic protocol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Traditional diagnostic protocol
Number of subjects: 18
Study: 21988071

Group type: EXPERIMENTAL
Intervention: Extra credit (social reward)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equivalent cash reward (monetary reward)
Number of subjects: 0
Study: 19845969

Group type: EXPERIMENTAL
Intervention: 1600 IU/day natural (RRR) alpha tocopherol for 20 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100, 200, 400, 800 or 1600 IU/day of natural (RRR) alpha tocopherol
Number of subjects: 20
Study: 17520464

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate foam 0.05%
Number of subjects: 24
Study: 15154364

Group type: EXPERIMENTAL
Intervention: Selenes‐korona rehabilitation complex
Number of subjects: 0
Study: 12205733

Group type: EXPERIMENTAL
Intervention: Tubeless group (n=56)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Intubated group (n=63)
Number of subjects: 119
Study: 9814469

Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) at doses of 40 mg, 20 mg, and 10 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Subcutaneous testosterone implant (100 mg)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Transdermal delivery system (TD1, TD2, TD3)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (study 2 control group)
Number of subjects: 46
Study: 7662600

Group type: EXPERIMENTAL
Intervention: Nicorandil (20 mg single oral dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (20 mg single oral dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Nicorandil (2 x 20 mg/day for 8 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (3 x 20 mg/day for 8 days)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (2 x 20 mg/day for 8 days)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Nicorandil and Isosorbide dinitrate
Number of subjects: 24
Study: 2727638

Group type: EXPERIMENTAL
Intervention: 800 mg bacampicillin
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 1000 mg amoxycillin
Number of subjects: 8

Group type: COMPARATOR
Intervention: Omeprazole (potent acid inhibitor) pretreatment
Number of subjects: 8
Study: 796645

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (1500 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibuprofen (1200 mg/day)
Number of subjects: 0
Study: 31229207

Group type: EXPERIMENTAL
Intervention: Usual care plus nurse-led survivorship model of care (3 face-to-face appointments, tailored resources, SCPTS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 60
Study: 28720233

Group type: EXPERIMENTAL
Intervention: Reflexology (20 min, twice a week for 24 sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study: 26377190

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle program
Number of subjects: 649
Study: 23619129

Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) treatment in treated patients (n=16)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Blood pressure (BP) treatment
Number of subjects: 20
Study: 21411612

Group type: EXPERIMENTAL
Intervention: CasMag-stabilized emulsion containing 30% solid fat
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (egg lecithin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (13)C-labeled mixed TG in CasMag emulsion
Number of subjects: 20
Study: 19667978

Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 93
Study: 17944981

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times a week for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 17
Study: 16331761

Group type: EXPERIMENTAL
Intervention: 15 microg PVAC
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50 microg PVAC
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11782059

Group type: EXPERIMENTAL
Intervention: Hierarchical generalized linear models
Number of subjects: 0
Study: 9616526

Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone for 3 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 20
Study: 8131334

Group type: EXPERIMENTAL
Intervention: Active ankle movement and weight bearing in an orthosis
Number of subjects: 53

Group type: COMPARATOR
Intervention: No ankle movement but weight bearing in a walking cast
Number of subjects: 53
Study: 2683851

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 30
Study: 31802716

Group type: EXPERIMENTAL
Intervention: Intravenous thyroxine (T4) infusion for 8 hours
Number of subjects: 28

Group type: COMPARATOR
Intervention: No T4 infusion (control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravenous thyroxine (T4) infusion for 8 hours (in donors with a history of drug use)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No T4 infusion (control) (in donors without a history of drug use)
Number of subjects: 28
Study: 31294768

Group type: COMPARATOR
Intervention: Phacoemulsification with intraocular lens implantation (PEI) alone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Phacoemulsification with intraocular lens implantation and goniosynechialysis (PEI-GSL)
Number of subjects: 78
Study: 27624670

Group type: EXPERIMENTAL
Intervention: Daunorubicin/clofarabine (DClo)
Number of subjects: 806

Group type: COMPARATOR
Intervention: Daunorubicin/ara-C (DA)
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Clofarabine 20 mg/m2 for 5 days with daunorubicin
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of relapse
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Survival from relapse
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Relapse-free survival
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 806
Study: 25216939

Group type: EXPERIMENTAL
Intervention: Laser preconditioning (Er,Cr:YSGG laser)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham laser (negative control)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Composite curing light (positive control)
Number of subjects: 6
Study: 23701921

Group type: EXPERIMENTAL
Intervention: Intervention group (3 UMCs)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group (3 UMCs)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Communication materials (posters)
Number of subjects: 6
Study: 19756376

Group type: EXPERIMENTAL
Intervention: Bevacizumab combination therapy
Number of subjects: 2860
Study: 19615130

Group type: EXPERIMENTAL
Intervention: Continuous high-volume hemofiltration (HVHF) at 6 L/h for 24 hours
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no HVHF treatment)
Number of subjects: 41
Study: 15614149

Group type: EXPERIMENTAL
Intervention: Valganciclovir or oral ganciclovir prophylaxis for 100 days
Number of subjects: 0
Study: 10427657

Group type: EXPERIMENTAL
Intervention: Remicade (Infliximab)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 0
Study: 8561997

Group type: EXPERIMENTAL
Intervention: 6-month program of educational videos, small group discussions, pictorial educational materials, and free condom distribution
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 334
Study: 2312776

Group type: EXPERIMENTAL
Intervention: metoprolol CR/ZOK 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: conventional metoprolol 50 mg tablets
Number of subjects: 12
Study: 6903108

Group type: EXPERIMENTAL
Intervention: Adrenaline 1% + Guanethidine 5%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5% + Guanethidine 3%
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.2% + Guanethidine 1%
Number of subjects: 3

Group type: COMPARATOR
Intervention: Pilocarpine
Number of subjects: 3

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 3
Study: 31184958

Group type: EXPERIMENTAL
Intervention: 4-week progression-based balance-training program
Number of subjects: 15
Study: 28327116

Group type: EXPERIMENTAL
Intervention: Tailored, interactive online safety and health intervention (iCAN Plan 4 Safety)
Number of subjects: 450

Group type: COMPARATOR
Intervention: General online safety information (usual care)
Number of subjects: 450
Study: 26408865

Group type: EXPERIMENTAL
Intervention: Active stimulation
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 9
Study: 23406320

Group type: EXPERIMENTAL
Intervention: High-dose intradermal (ID) vaccine
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard-dose intramuscular (IM) vaccine
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 212
Study: 20071637

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Methylphenidate (open-label trial)
Number of subjects: 116
Study: 19822836

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus cognitive behavioral skills training telephone intervention
Number of subjects: 2151
Study: 17628319

Group type: EXPERIMENTAL
Intervention: ERC 2005 guidelines
Number of subjects: 34

Group type: COMPARATOR
Intervention: ERC 2000 guidelines
Number of subjects: 34
Study: 15128912

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83

Group type: COMPARATOR
Intervention: NAC or placebo
Number of subjects: 83
Study: 11824485

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 122
Study: 9509949

Group type: COMPARATOR
Intervention: Total antioxidant status in mild pre-eclampsia
Number of subjects: 75

Group type: COMPARATOR
Intervention: Total antioxidant status in severe pre-eclampsia
Number of subjects: 75

Group type: COMPARATOR
Intervention: Total antioxidant status in eclampsia
Number of subjects: 75
Study: 7995187

Group type: EXPERIMENTAL
Intervention: Loperamide treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29925419

Group type: EXPERIMENTAL
Intervention: Pro Kind home-visiting program
Number of subjects: 755

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 755
Study: 26633243

Group type: EXPERIMENTAL
Intervention: Self-administered taste test using 'Taste Strips' (mean score 12.3 ± 2.6)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Examiner-administered taste test using 'Taste Strips' (mean score 11.6 ± 2.6)
Number of subjects: 65
Study: 24146170

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg once weekly with calcium and vitamin D supplementation
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo with calcium and vitamin D supplementation
Number of subjects: 131
Study: 23343671

Group type: EXPERIMENTAL
Intervention: Protein Blend (PB) - ∼19 g
Number of subjects: 19

Group type: COMPARATOR
Intervention: Whey Protein (WP) - ∼18 g
Number of subjects: 19
Study: 21348207

Group type: EXPERIMENTAL
Intervention: kidney‐tonifying and dampness‐expelling Chinese herbal decoction combined with doxazosin
Number of subjects: 64

Group type: COMPARATOR
Intervention: doxazosin only
Number of subjects: 64
Study: 19840533

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 67

Group type: COMPARATOR
Intervention: Both bisoprolol and perindopril
Number of subjects: 67
Study: 16717293

Group type: EXPERIMENTAL
Intervention: Cetuximab (initial dose 400 mg/m2, subsequent weekly doses 250 mg/m2) in combination with cisplatin (100 mg/m2) and fluorouracil (FU) (escalating doses of 600, 800, and 1,000 mg/m2/d)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Cetuximab (initial dose 400 mg/m2, subsequent weekly doses 250 mg/m2) in combination with carboplatin (AUC 5) and fluorouracil (FU) (escalating doses of 600, 800, and 1,000 mg/m2/d)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Combination therapy (cetuximab, cisplatin/carboplatin, and FU)
Number of subjects: 53
Study: 15572537

Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 511

Group type: COMPARATOR
Intervention: Clarithromycin
Number of subjects: 511
Study: 11737876

Group type: EXPERIMENTAL
Intervention: UVA irradiation administered with an air-conditioned sunbed, cumulative UVA dose: 96 J/cm2, two exposures weekly for three weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: No UVA exposures (Control group)
Number of subjects: 24
Study: 9240635

Group type: EXPERIMENTAL
Intervention: Helium-Neon laser treatment (632.8 nm wavelength, power 60 mW), applied daily from d-5 to d-1 on five anatomic sites of the oral mucosa.
Number of subjects: 30
Study: 8260235

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with BCNU 80 mg/m2 i.v. every 4 weeks, actinomycin-D 10 micrograms/kg, vincristine 1.0 mg/m2 i.v. every 2 weeks for 6 months
Number of subjects: 173

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 173
Study: 3653755

Group type: EXPERIMENTAL
Intervention: Rectal distension during fasting
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Rectal distension postprandially
Number of subjects: 6
Study: 31668839

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus oxaliplatin (GEMOX) - gemcitabine 1000 mg/m2, oxaliplatin 100 mg/m2 on day 1 every 2 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gemcitabine plus carboplatin (GCb) - gemcitabine 1000 mg/m2 on day 1 and day 8, carboplatin AUC 4.5 mg/mL/min on day 1 every 3 weeks
Number of subjects: 80
Study: 29902447

Group type: EXPERIMENTAL
Intervention: Belladonna and opiate suppository (16.2/7.5 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 26